Exit Strategy Signals Eyenovia is actively pursuing strategic alternatives, including a potential sale, merger, or asset sale, with Chardan Capital Markets engaged as an advisor. A PIPE financing of about fifty million dollars completed in 2025 signals liquidity and investor interest that could enable a quick transition or partnership with a larger player.

Optejet Licensing Potential The Optejet device platform drives the company’s pipeline by pairing with its own presbyopia and pediatric progressive myopia drug-device candidates, and it is open to out-licensing for additional indications. Potential business development plays include licensing or co-development partnerships with larger ophthalmology companies and potential integration with Betaliq’s EyeSol drug delivery technology.

Crypto Pivot Recent announcements show a shift into digital assets and blockchain, including a co-branded validator node on the Hyperliquid network and a partnership with Anchorage Digital, plus leadership hires to support crypto treasury strategy. This could create opportunities to collaborate with crypto-focused investors or financing structures that support growth initiatives.

Funding Growth Readiness With a small revenue base and a lean team, Eyenovia may rely on licensing milestones or asset deals rather than internal scale-up. The combination of financing activity, strategic advisory appointments, and ongoing evaluation of strategic options suggests openness to monetizing assets through third-party deals with bigger pharma or investment groups.

Market Access Opportunities The company targets ophthalmic care markets for presbyopia and pediatric myopia, offering a device-led delivery platform that could be deployed via clinics or licensed to partners. Opportunities exist in direct partnerships with ophthalmology networks, collaborations with larger pharmaceutical players for device-drug combinations, and potential acquisition by a larger eye-care company seeking to augment its device platform.